InfuSystem Holdings, Inc. - 10-Q Summary (Period Ended Sep 30, 2009)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2009, and the nine months ended on that date. InfuSystem Holdings, Inc. (formerly HAPC, Inc.) is a provider of ambulatory infusion pump management services, primarily for oncology patients receiving chemotherapy. The company rents electronic pumps and supplies to over 1,300 oncology practices in the United States. As of November 1, 2009, 18,676,630 shares of common stock were outstanding.
Key Financial Metrics
| Metric (in thousands) | 9 Months Ended Sep 30, 2009 | 9 Months Ended Sep 30, 2008 | 3 Months Ended Sep 30, 2009 | 3 Months Ended Sep 30, 2008 |
|---|---|---|---|---|
| Net Revenues | $28,302 | $26,323 | $9,902 | $8,958 |
| Operating Income | $3,968 | $3,248 | $1,363 | $1,648 |
| Net (Loss) Income | $(192) | $8,700 | $(445) | $5,704 |
| Cash from Operations | $7,074 | $9,270 | N/A | N/A |
| Cash and Equivalents (End of Period) | $6,716 | $10,795 | $6,716 | $10,795 |
| Total Debt (Current + Long-term) | $23,892 | $23,892 | $23,892 | $23,892 |
| Derivative Liabilities | $3,793 | $2,592 | $3,793 | $2,592 |
Note: Debt figures represent total contractual obligations including capital leases. The term loan balance with I-Flow was $22,503,000 as of September 30, 2009.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 8% year-over-year for the nine-month period ($28.3M vs $26.3M) and 11% for the quarter ($9.9M vs $9.0M), driven by new customer facilities and increased reimbursement rates.
- Profitability Shift: The company reported a net loss of $192,000 for the nine months ended September 30, 2009, compared to a net income of $8.7 million in the prior year. This reversal is primarily due to a $1.2 million loss on derivatives in 2009 versus an $8.7 million gain in 2008.
- Operating Expenses: General and administrative expenses increased 18% for the quarter ($3.2M vs $2.7M), largely due to compensation and benefits recognized for the former CEO under a separation agreement. Cost of revenues increased 20% for the quarter but only 1% for the nine months.
- Liquidity: Cash and cash equivalents decreased by $4.8 million to $6.7 million, primarily due to $7.7 million in principal debt payments and $4.0 million in capital expenditures.
Guidance, Outlook, and Risks
- Management Outlook: Management anticipates revenue growth from expanding pump usage for colorectal, head, neck, and gastric cancers. They do not believe the global financial crisis will materially impact operations or liquidity for the next 12 months.
- Executive Changes: Steve Watkins resigned as CEO on September 7, 2009. Sean McDevitt was appointed CEO and Executive Chairman. A separation agreement with Mr. Watkins includes two years of base salary and a $150,000 bonus.
- Derivative Volatility: The company holds 33.75 million warrants classified as liabilities. Changes in the fair value of these warrants significantly impact net income, as evidenced by the swing from an $8.7M gain in 2008 to a $1.2M loss in 2009.
- Debt Covenants: The company is subject to covenants regarding fixed charge coverage, leverage, and minimum EBITDA. Management believes it is in compliance. The term loan prohibits dividends and equity retirements.
- Contingencies: An earn-out provision exists for up to $12 million payable to I-Flow in 2011 if revenue targets are met. Additionally, I-Flow (the lender) announced an acquisition by Kimberly-Clark Corporation, which is binding on the loan agreement.
Investor Verification Checklist
- Derivative Liability Impact: Verify the sensitivity of net income to fluctuations in the market price of the 33.75 million outstanding warrants.
- Debt Service Capacity: Confirm continued compliance with I-Flow debt covenants (fixed charge coverage and EBITDA) given the recent net loss.
- Accounts Receivable Quality: Review the allowance for doubtful accounts ($1.58M) and the $4.2M increase in receivables during the nine-month period to assess collection risks.
- CEO Transition Costs: Monitor the impact of the former CEO's separation agreement on future operating expenses.
- Reimbursement Rates: Assess the sustainability of revenue growth given the heavy reliance on Medicare (31% of gross billings) and Blue Cross/Blue Shield (22% of gross billings).